Collaboration Agreements (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Mar. 29, 2014	Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense		$ (187.8)	$ (152.5)	$ (115.2)
Potential contingent milestone payments		30.0
Royalty revenue, percent of net sales	6.50%
Revenues				0.8
Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential contingent milestone payments	$ 10.0			0.5
Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential contingent milestone payments	$ 15.0			2.0
Gelcaps [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense		(78.0)
Biotech [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense		(10.0)
Potential contingent milestone payments		50.0
Phase three [Member] | Biotech [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense		(5.0)
Final phase [Member] | Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential contingent milestone payments				3.8
Final phase [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential contingent milestone payments				$ 5.5
Final phase [Member] | Gelcaps [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense		(105.0)
Final phase [Member] | Biotech [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense		(10.0)
Topical product [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential contingent milestone payments		17.5
contractual arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense		$ (18.0)